

Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and to applicable state and/or federal laws.

Chemoembolization (CE) for Hepatic Tumors

MP9462

Covered Service: Yes

Prior Authorization

Required: No

Additional

Information: None

Prevea360 Health Plan Medical Policy:

- 1.0 Chemoembolization (CE) for hepatic tumors **does not** require prior authorization and is considered medically necessary for **ANY** of the following indications:
 - 1.1 For treatment of hepatitis metastases from neuroendocrine tumors;
 - 1.2 For the treatment of unresectable, primary hepatocellular carcinoma.;
- 2.0 Chemoembolization for hepatic tumors is considered experimental and investigational, and therefore is not medically necessary for all other indications.



Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and to applicable state and/or federal laws.

	Committee/Source	Date(s)
Document Created:	Medical Policy Committee/Quality and Care Management Division	June 15, 2016
Revised:	Medical Policy Committee/Quality and Care Management Division Medical Policy Committee/Health Services Division	July 19, 2017 August 15, 2018 August 21, 2019 August 18, 2021 August 17, 2022 November 16, 2022 August 16, 2023 March 20, 2024
Reviewed:	Medical Policy Committee/Quality and Care Management Division Medical Policy Committee/Health Services Division	July 19, 2017 August 15, 2018 August 21, 2019 August 19, 2020 August 18, 2021 August 17, 2022 November 16, 2022 August 16, 2023 March 20, 2024

Published: 04/01/2024 Effective: 04/01/2024